AI in Bio + Health

Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health. Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab.

Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.

Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.

Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.

This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.

Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.

Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.

Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.

Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.

In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.

We have long believed that AI will fundamentally reshape biotech and healthcare, positioning us at the brink of an AI-driven Industrial Revolution. But when will we see this payoff? Put more boldly, when will the majority of new drugs be designed with AI?

Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit. Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences.

Bio Eats World is now Raising Health! On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.

100% of stock trades used to be made by humans. Today, 80% are made by computer algorithms. AI is about to bring a similar revolution to healthcare. Over the next few decades, at least half of the $4.3 trillion dollar American healthcare industry will be AI-driven.

Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health. In this episode, Pranav and Vijay discuss a future with generalist medical AI. This is the idea of a medical AI that isn’t narrowly tailored to one specific task.

Mario Schlosser, cofounder, former CEO, and current President of Technology at Oscar Health, joins Julie Yoo of Bio + Health. The conversation explores how AI advancements can revolutionize traditional healthcare models by enhancing efficiency, personalizing care journeys, and integrating real-time data insights.

Our view is that 1) the latest advancements in AI offer a massive enablement opportunity to support our clinicians and 2) this can’t happen without the help of forward-thinking policymakers laying the infrastructure for AI-enabled care.

Miriam Vogel, President and CEO of EqualAI, cohost of the podcast In AI we Trust, and Chair to the recently launched National AI Advisory Committee, joins Vijay Pande of Bio + Health.

While the Google --> WebMD --> Friend protocol may be a common way to enter into the healthcare system, it is certainly not an optimal one. Most of us are not well-equipped to self-diagnose from a list of possible conditions, and our friends who work in healthcare often don’t have the exact expertise we need.

AI trailblazer Suchi Saria, PhD, in conversation with Vijay Pande, sheds light on the winding path that led her to launch Bayesian Health, a bold effort to infuse intelligence into clinical workflows.

In this candid conversation, Li unfolds her transformation from a young immigrant to an influential figure in AI. The conversation explores the birth of ImageNet, a pivotal step that bridged the gap between visual intelligence and accessible AI technology.

Together, they talk about how Evan’s work in the lab (ironically, Vijay's lab at Stanford!) translated to the creation of Genesis, which is tackling the problem of drug discovery through AI. They also discuss how the Genesis team is building specifically to carry on work at the intersection of ML, biotech, and chemistry.

Surya Ganguli, PhD, an associate professor at Stanford University and a neural dynamics researcher, joins Vijay Pande of Bio + Health.

This episode is live from our recent AI Revolutionaries (AIR) conference. In this episode, Daphne Koller, PhD, founder and CEO at insitro and AI expert, chats with Vijay Pande of Bio + Health.

Aviv Regev, PhD, the Head and Executive VP of Genentech Research and Early Development, and founding co-chair of the Human Cell Atlas, joins Vijay Pande on Bio Eats World.

Insights from leaders at OpenAI, Microsoft, Anthropic, Databricks, Character.AI, Roblox, insitro, and Figma on where we are, where we're going, and the open questions for building the next wave of AI.

Daphne Koller, founder and CEO of insitro, discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultural divide between building with atoms and building with bits.

Andrew has thought deeply about the implications of integrating AI into many areas of our lives, going so far as to put out a public social media call for people who believe AI is dangerous to speak with him. He and Vijay discussed this, as well as how AI could become foundational to many industries—and what needs to happen to make that future a reality.

Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.

Together, Lloyd and Vijay chatted about how AI could change the practice of medicine, and what the implications are for medical students now and in the future. join Lloyd and Vijay as they discuss AI and medical education—from how students learn to how doctors become licensed.

Isaac (Zak) Kohane, MD, PhD, the Chair of the Department of Biomedical Informatics at Harvard Medical School, joins Vijay Pande, founding partner of a16z Bio + Health.

We believe that any new technology has to be 10 times better to successfully displace the last one – marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.

Amy Abernethy, former Principal Deputy Commissioner at the FDA and now the President of Product Development and Chief Medical Officer at Verily Life Sciences, joins Vijay Pande, founding partner of a16z Bio + Health.

Today’s episode is with Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS). He is joined by a16z Bio + Health general partner Jorge Conde.

In this episode, Daphne Koller, founder and CEO of insitro, chats with a16z Bio + Health founding partner Vijay Pande.

In this episode, Vijay Pande, founding partner of a16z Bio + Health, talks with Jakob Uszkoreit, the cofounder of Inceptive, about the past and future of AI — and how AI can be used to push the science of biology farther.

In this episode, Marc Andresseen and Vijay Pande discuss expert AI and its role in healthcare, bio, and more.

Eric Topol joins a16z Bio + Health general partners Vijay Pande and Vineeta Agarwala and editorial lead Olivia Webb to talk about where AI in healthcare is going, where AI can help patients and providers the most, and what needs to happen to achieve widespread adoption.

Featuring Suchi Saria, PhD, and the CEO of Bayesian Health; Neri Cohen, MD, PhD, as well as a collaborator with Bayesian Health; and Vineeta Agarwala, MD, PhD, and a16z general partner. Hosted by Olivia Webb.

Rick Young is a professor of biology at MIT who studies RNA that is transcribed from the part of the genome that does not code for proteins, known as non-coding DNA. This part of the genome was once referred to as ‘junk...

In today’s episode we have two short segments, both on bioscience topics.

On today’s episode, we are making the full arc from the theoretical and borderline philosophical to the applied. Let’s start with the theory: embodied intelligence posits that the body, or the physical form, plays an act...

We’ve come a long way from having to make the case for artificial intelligence (AI) in biology. Just a few years ago, I argued in The New York Times how fears around the “black box” of AI in medicine are often misplaced...

On the path from scientific discovery to new drug, the clinical trial is a huge — and critical — hurdle. Clinical trials are themselves experiments, and to make sure that they are doing the best possible job at determini...

In this episode, we talk with Jeff Hawkins—an entrepreneur and scientist, known for inventing some of the earliest handheld computers, the Palm and the Treo, who then turned his career to neuroscience and founded the Red...

There's been a lot of talk (including on this show!) about the many kinds of innovations and technologies changing healthcare delivery for clinicians and patients. But what's happening behind the scenes in healthcare: in...

It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.

It's Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.

All kinds of decisions, whether in life or business -- like marriage product management, what to eat or watch -- are a portfolio of investments. And obviously, not all decisions are equal; in fact, sometimes we don't even have to spend any time deciding. So how do we know which decisions to spend time on, which ones not to? What are the strategies, mindsets, tools to help us decide? How can we operationalize good decision hygiene into our teams and organizations? We cover all this and more in this early podcast with Annie Duke for her new book, How to Decide.

a16z Journal Club covers recent advances from the scientific literature; this inaugural episode for bio covers 2 two different topics: (1) identifying new antibiotics through a novel machine-learning based approach; and (2) characterizing the novel coronavirus causing the COVID-19 pandemic.

Bioengineering, once viewed primarily as an academic discipline, is growing up.

The idea of reverse engineering biology seems like a paradox. How could we ever reverse engineer anything for which we didn’t “invent” the original technology? Radios, bridges, computers—all these are human-made, built f...

One of the defining characteristics in an industrial revolution is the fundamental shift from a bespoke, artisan process to an industrialized, engineerable, repeatable one. In this video, general partner on the Bio Fund...

We are at the beginning of a new era, where biology has shifted from an empirical science to an engineering discipline. After a millennia of using man-made approaches for controlling or manipulating biology, we have fina...

Artificial intelligence is coming to the doctor’s office. In this episode, Dr. Eric Topol, cardiologist and chair of innovative medicine at Scripps Research, and a16z’s general partner on the Bio Fund Vijay Pande, have a...

Bharath Ramsundar, Peter Eastman, Pat Walters, and I wrote Deep Learning for the Life Sciences with one primary message in mind: you can easily now do world-class AI in Bio from your laptop. Bringing AI to the life scien...

The greatest problem of health care in United States – the world leader in health inequality – isn’t actually about the quality of care. The greatest problem we have is access to care. According to the CDC, nearly 20% of...

watch/listen time: 22 minutes

The discovery of small molecule drugs follows a well-honed playbook. You first discover the drug target, then discover the lead drugs that can hit those targets, optimize those leads, and then enter pre-clinical testing....

watch time: 23 minutes

What do disease diagnostics, language learning, and image recognition have in common? All depend on the organization of collective intelligence: data ontologies. In this episode of the a16z Podcast, guests Luis von Ahn,...

watch time: 4 minutes

watch time: 13 minutes

Soylent’s mission is to use cutting-edge science and engineering to create nutritious food that is convenient and affordable to everyone in the world. We hope that Soylent will one day be a staple in every home — as ubiq...